Badania trwające

Badania planowane


Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab.


A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA).

Badania zakończone


An Adaptive Randomized Phase 3 Comparison of Standard Platinum Based Treatment versus Platinum And TSR-042 Followed by Niraparib and TSR-042 Maintenance Therapy in Patients With Epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum.

AGO-OVAR 23 / DUO-O / D081RC00001 / ENGOT-ov46

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients.

ARAVIVE / ENGOT OV66 / GEICO 104-O study

“A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer study.


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy.

D0816C00014 / ENGOT-ov38 / OReO

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.

ENGOT-ov50 / GOG-3029 / INNOVATE-3

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weeklypaclitaxel for the treatment of platinum-resistant ovarian cancer (PROC).


Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer ( ENGOT-ov65 /KEYNOTE-B96)

IMGN853-0416 / GOG-3045 / ENGOT-OV55 / MIRASOL

A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

MER-XMT-1536-1 / ENGOT-ov67

A Phase 1b/2 First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.


Multicenter, Doubled-blinded, Randomized Phase III trial of Paclitaxel and Carboplatin, with/or without Pembrolizumab and with/or without Olaparib in BRCA wild type Advanced Tubo-Ovarian Carcinoma.

YO39523 / IMagyn050/ GOG 3016/ ENGOT ov39

A Phase III, multicenter, randomized study of Atezolizumab Versus Placebo administered in combination with paclitaxel, carboplatin, and bevacizumab for patients with newly‑diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

Badania trwające

Badania planowane

Umowa w trakcie negocjacji

Badania zakończone

ENGOT-cx12/ SGNTV-003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer.

R2810-ONC-1676 / ENGOT CX9 / GEICO 72-C

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator’s Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma.

Badania trwające


A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

Badania planowane

Umowa w trakcie negocjacji

KRT-232-118 ENGOT-en21 A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Badania zakończone

D9311C00001 / ENGOT-EN10 / DUO-E

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer.

ENGOT-en6/ GOG 3031

A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer.

KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent.

MK-7902-001 / E7080-G000-313 / ENGOT-EN9

A Phase 3 Randomized, Open-Label, Trial of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma.